Facing up to the diagnostic uncertainty and management of onychomycoses

International Journal of Dermatology

Volumn 38, Issue SUPPL. 2, 1999, Pages 1-6

  Arrese, Jorge E ^a   Piérard Franchimont, Claudine ^a   Piérard, Gérald E ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; FUNGICIDE; ITRACONAZOLE; TERBINAFINE;

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; ONYCHOMYCOSIS; PREVALENCE;

EID: 0344980148     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1999.00007.x     Document Type: Article

References (63)

1. Williams HC. The epidemiology of onychomycosis in Britain. Br J Dermatol 1994; 129: 101-109.
2. Scher RK. Onychomycosis: a significant medical disorder. J Am Acad Dermatol 1996; 35: S2-S5.
3. Gupta AK, Jain HC, Lynde CW, et al. Prevalence of unsuspected onychomycosis in patients visiting dermatologists offices in Ontario, Canada: a multicenter study of 2001 patients. Int J Dermatol 1997; 36: 783-787.
4. Whittam LR, Hay R. The impact of onychomycosis on quality of life. Clin Exp Dermatol 1997; 22: 87-89.
5. Clayton YM. Clinical and mycological diagnostic aspects of onychomycoses and dermatomycoses. Clin Exp Dermatol 1992; 17 (Suppl. 1): 37-40.
6. Piérard GE, Arrese JE, Pierre S, et al. Diagnostic microscopique des onychomycoses. Ann Dermatol Venereol 1994; 121: 25-29.
7. Arrese JE, Piérard-Franchimont C, Piérard GE. A review of the clinical and histological presentations of onychomycoses. Turk J Dermatopathol 1993; 2: 175-178.
8. Arrese JE, Piérard-Franchimont C, Greimers R, Piérard GE. Fungi in onychomycosis. A study by immunohistochemistry and dual flow cytometry. J Eur Acad Dermatol Venereol 1995; 4: 123-130.
9. Piérard GE, Arrese JE, De Doncker P, Piérard-Franchimont C. Present and potential diagnostic techniques in onychomycosis. J Am Acad Dermatol 1996; 34: 283-277.
10. Evans EGV. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol 1998; 38: S32-S36.
11. Piérard GE, Piérard-Franchimont C, Arrese JE. Onychomycoses may be caused by facultative pathogenic molds. Dermatopathology 1998; 4: 131-132.
12. Shuster S. Onychomycosis: making sense of the assessment of anti-fungal drugs. Acta Derm Venereol (Stockh) 1998; 78: 1-4.
13. Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis and tinea manuum caused by nondermatophytic filamentous fungi. Mycoses 1989; 32: 609-610.
14. Greer DL. Evolving role of nondermatophytes in onychomycosis. Int J Dermatol 1995; 34: 521-524.
15. Arrese JE, Piérard-Franchimont C, Piérard GE. Fatal hyalohyphomycosis following Fusarium onychomycosis in an immuno-compromised patient. Am J Dermatopathol 1996; 18: 196-198.
16. Arrese JE, Piérard-Franchimont C, Piérard GE. Onychomycosis and keratomycosis caused by Alternaria sp. A bipolar opportunistic infection in a wood-pulp worker on chronic steroid therapy. Am J Dermatopathol 1996; 18: 611-613.
17. Ginter G, Rieger E, Heigl K, et al. Increasing frequency of onychomycoses. Is there a change in the spectrum of infectious agents? Mycoses 1996; 39: S118-S122.
18. Gupta AK, Elewski BE. Nondermatophyte causes of onychomycosis and superficial mycoses. Curr Top Med Mycol 1996; 7: 87-97.
19. Elewski BE. Large-scale epidemiological study of the causal agents of onychomycosis: mycological findings from the multicenter onychomycosis study of terbinafine. Arch Dermatol 1997; 133: 1317-1318.
20. Piérard GE, Arrese Estrada J, Piérard-Franchimont C. Treatment of onychomycosis. Traditional approaches. J Am Acad Dermatol 1993; 29: S41-S45.
21. Hay RJ. Onychomycosis. Agents of choice. Dermatol Clin 1993; 11: 161-169.
22. Roseeuw D, De Doncker P. New approaches to the treatment of onychomycosis. J Am Acad Dermatol 1993; 29: S45-S50.
23. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911-933.
24. Odom RB. New therapies for onychomycosis. J Am Acad Dermatol 1996; 35: S26-S30.
25. Elewski BE. Onychomycosis: pathogenesis, diagnosis and management. Clin Microbiol Rev 1998; 11: 415-429.
26. Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs 1996; 52: 209-224.
27. Piérard GE, Arrese JE, De Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol 1995; 32: 429-435.
28. Matthieu L, De Doncker P, Cauwenbergh G, et al. Itraconazole penetrates the nail via the nail matrix and nail bed - an investigation in onychomycosis. Clin Exp Dermatol 1991; 16: 374-376.
29. Hay RJ. Pharmacokinetic evaluation of fluconazole in skin and nails. Int J Dermatol 1992; 31 (Suppl. 2): 6-7.
30. Willemsen M, De Doncker P, Willems J, et al. Posttreatment itraconazole levels in the nail. J Am Acad Dermatol 1992; 26: 731-735.
31. Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum) sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121-126.
32. Leyden J. Pharmacokinetics and pharmacology of terbinafine and itraconazole. J Am Acad Dermatol 1998; 38: S42-S47.
33. Savin RC, Drake L, Babel D, et al. Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300 or 450 mg) in distal subungual onychomycosis of the fingernail. J Am Acad Dermatol 1998; 38: S110-S116.
34. Bräutigam M, Nolting S, Schopf RE, et al. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Br Med J 1995; 311: 919-922.
35. De Backer M, De Keyser P, De Vroey C, et al. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day - a double-blind comparative trial. Br J Dermatol 1996; 134 (Suppl. 46): 16-17.
36. Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34: 595-600.
37. Gupta AK, Shear NH. Terbinafine: an update. J Am Acad Dermatol 1997; 37: 979-988.
38. Svejgaard EL, Brandrup F, Kragballe K, et al. Oral terbinafine in toenail dermatophytosis. Acta Derm Venereol (Stockh) 1997; 77: 66-69.
39. Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997; 37: 740-745.
40. De Doncker P, Van Lint J, Dockx P, et al. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis 1995; 56: 180-183.
41. De Doncker P, Decroix J, Piérard GE, et al. Antifungal pulse therapy in onychomycosis: a pharmacokinetic/ pharmacodynamic investigation of monthly cycles of 1 week pulse with itraconazole. Arch Dermatol 1996; 132: 34-41.
42. Haneke E, Delescluse J, Plinck EPB, et al. The use of itraconazole in onychomycosis. Eur J Dermatol 1996; 6: 7-10.
43. Piérard GE, Piérard-Franchimont C. Traitement des mycoses de la peau et des ongles par l'itraconazole. Le nouveau concept de la thérapie intermittente par modules hebdomadaires répétés mensuellement. Rev Med Liege 1996; 51: 729-730.
44. Bonifaz A, Carrasco-Gerard E, Saul A. Itraconazole in onychomycosis: intermittent dose schedule. Int J Dermatol 1997; 36: 70-72.
45. De Doncker P, Gupta AK, Marynissen G, et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1997; 37: 969-974.
46. Havu V, Brandt H, Heikkilä H, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol 1997; 136: 230-234.
47. Piérard GE. Comment je traite une onychomycose par thérapie pulsée. Rev Med Liege 1997; 52: 379-381.
48. Gupta AK, De Doncker P, Scher RK, et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998; 37: 303-308.
49. Nolting SK, Sanchez Corazo J, De Boulle K, Lambert JR. Oral treatment schedules for onychomycosis: a study of patient preference. Int J Dermatol 1998; 37: 454-456.
50. Nahass GT, Sisto M. Onychomycosis: successful treatment with once-weekly fluconazole. Dermatology 1993; 186: 59-61.
51. Kuokkanen K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992; 3: 115-117.
52. Assaf RR, Elewski BE. Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. J Am Acad Dermatol 1996; 35: 216-219.
53. Montero-Gei F, Robles-Soto ME, Schlager H. Fluconazole in the treatment of severe onychomycosis. Int J Dermatol 1996; 35: 587-588.
54. Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatments of distal subungueal onychomycosis of the toenail. J Am Acad Dermatol 1998; 38: S77-S86.
55. Ling MR, Swinyer LJ, Jarratt MT, et al. Once-weekly fluconazole (450 mg) for 4, 6 or 9 months of treatment for distal subungueal onychomycosis of the toenail. J Am Acad Dermatol 1998; 38: S95-S102.
56. Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. Pharmacoeconomics 1998; 13: 243-256.
57. Tosti A, Piraccini BM, Mariani R, et al. Are local and systemic conditions important for the development of onychomycosis? Eur J Dermatol 1998; 8: 41-44.
58. Hay RJ, Baran R, Moore MK, et al. Candida onychomycosis: an evaluation of the role of Candida species in nail disease. Br J Dermatol 1988; 118: 47-58.
59. Nolting S, Bräutigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatoytic fungi. Br J Dermatol 1994; 130: 16-21.
60. Segal R, Kritzman A, Cividalli L, et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996; 35: 958-961.
61. Tosti A, Piraccini BM, Stinchi C, et al. Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals. Br J Dermatol 1996; 135: 799-802.
62. De Doncker P, Scher RK, Baran RL, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997; 36: 173-177.
63. Ellis DH, Watson AB, Marley JE, et al. Non-dermatophytes in onychomycosis of the toenails. Br J Dermatol 1997; 136: 490-493.